Welcome to our dedicated page for Cell Source SEC filings (Ticker: CLCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cell Source's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cell Source's regulatory disclosures and financial reporting.
Cell Source, Inc. files its annual report describing an early-stage cell therapy business focused on Veto Cell immunotherapy. The company is developing CD8 central memory Veto Cells and VETO CAR-T to make haploidentical stem cell transplants and off‑the‑shelf CAR‑T safer and more effective.
A Phase 1/2 trial at MD Anderson has shown reliable engraftment after reduced-intensity conditioning with low severe GvHD and no toxicity attributed to Veto Cells so far, but the company has no approved products, faces substantial clinical, regulatory and financing risks, and discloses substantial doubt about its ability to continue as a going concern.